The largest holder of Teva Pharmaceutical Industries stock is Harel Mutual Funds Ltd., with 72.3 million shares (6.21% of the company), worth about $2.58 billion as of September 25, 2026. The 10 largest holders together own 13.2%.
In Q2 2026, 724 institutional holdings reports listed 780.0 million shares worth $26.10 billion, up 15.4% in shares from Q1 2026.
Insiders reported 65 transactions in the last two years: 29 sales worth $70.25 million and 1 purchase. The newest one on file is from May 1, 2026 (Sabag Mark, Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 1, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Harel Mutual Funds Ltd. | 72.3 million | 6.21% | $2.6B |
| Menora Mivtachim Holdings Ltd. | 49.9 million | 4.28% | $1.8B |
| KSM Mutual Funds Ltd. | 12.2 million | 1.05% | $438.0M |
| Migdal Mutual Funds Ltd. | 6.9 million | 0.59% | $246.0M |
| IBI Mutual Funds Management (1978) Ltd. | 3.2 million | 0.28% | $115.0M |
| Psagot Mutual Funds Ltd. | 2.5 million | 0.21% | $90.0M |
| Phoenix Financial Ltd. | 2.2 million | 0.19% | $78.0M |
| Amir Elstein0.1818 % | 2.1 million | 0.18% | $76.0M |
| Ayalon Mutual Funds Ltd. | 1.6 million | 0.14% | $59.0M |
| Richard Francis0.101 % | 1.2 million | 0.10% | $42.0M |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 724 | 780.0 million | $26.1B |
| Q1 2026 | 701 | 676.0 million | $20.2B |
| Q4 2025 | 714 | 690.0 million | $21.5B |
| Q3 2025 | 628 | 731.0 million | $14.8B |
| Q2 2025 | 606 | 754.0 million | $12.5B |
| Q1 2025 | 619 | 714.0 million | $11.0B |
| Q4 2024 | 646 | 666.0 million | $14.6B |
| Q3 2024 | 599 | 638.0 million | $11.3B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Sabag Mark | May 1, 2026 | Officer | Sale at price 34.99 per share. | $5.0M |
| Fox Christine | Apr 30, 2026 | Officer | Sale at price 35.31 per share. | $750,620 |
| Sabag Mark | Mar 5, 2026 | Officer | -- | – |
| Kalif Eliyahu Sharon | Mar 5, 2026 | Chief Financial Officer | -- | – |
| Hughes Eric A | Mar 5, 2026 | Officer | -- | – |
| Fox Christine | Mar 5, 2026 | Officer | -- | – |
| Shields Matthew | Mar 5, 2026 | Officer | -- | – |
| Savage Brian | Mar 5, 2026 | Officer | -- | – |
| Francis Richard D | Mar 5, 2026 | Chief Executive Officer | -- | – |
| Francis Richard D | Mar 5, 2026 | Chief Executive Officer | Sale at price 31.67 per share. | $634,160 |
| Hughes Eric A | Mar 5, 2026 | Officer | Sale at price 31.67 per share. | $301,895 |
| Fox Christine | Mar 5, 2026 | Officer | Sale at price 31.67 per share. | $250,940 |
Newest 12 of 65 insider transactions in the last two years.
Harel Mutual Funds Ltd., with 6.21% of the company (as of September 25, 2026). Next: Menora Mivtachim Holdings Ltd. (4.28%) and KSM Mutual Funds Ltd. (1.05%).
724 institutional holdings reports listed Teva Pharmaceutical Industries shares in Q2 2026, 780.0 million shares in all worth $26.10 billion.
In the last two years insiders reported 29 sales and 1 purchase (65 transactions in all); the newest on file is from May 1, 2026.